Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 13/20 | 1.00 |
| ▸ | CTRC | Q99895 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CASP6 | P55212 | 2/20 | 0.56 |
| ▸ | NSD2 | O96028 | 1/20 | 0.56 |
| ▸ | MMP14 | P50281 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396122 | 1.00 | MPL (1.00) | MPLCTRCMEN1KMT2APOLB | |
| SCHEMBL737568 | 1.00 | MPL (1.00) | MPLCTRCMEN1KMT2APOLB | |
| SCHEMBL29395671 | 1.00 | MPL (1.00) | MPLCTRCMEN1KMT2APOLB | |
| SCHEMBL344193 | 0.85 | MPL (0.74) | MPLCTRCMEN1KMT2APOLB | |
| SCHEMBL344194 | 0.85 | MPL (0.74) | MPLCTRCMEN1KMT2APOLB | |
| SCHEMBL3346242 | 0.84 | CYP1A2 (0.73) | MPLCTRCMEN1KMT2APOLB | |
| SCHEMBL19940971 | 0.84 | MPL (0.72) | MPLCTRCMEN1KMT2APOLB | |
| SCHEMBL13804905 | 0.82 | MPL (0.70) | MPLCTRCMEN1KMT2APOLB | |
| SCHEMBL7247118 | 0.82 | MPL (1.00) | MPLCTRCMEN1KMT2AMAPT | |
| SCHEMBL29362358 | 0.82 | MPL (1.00) | MPLCTRCMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4283379-A | WASHING SOLUTION OF SOLUBILIZED VANADIUM, WATER SOLUBLE NONQUINONE AROMATIC COMPOUNDS, THIOCYANATE IONS, AND A CARBOXYLATE COMPLEXING AGENT | UNION OIL COMPANY OF CALIFORNIA (US) | 1981-08-11 | — | — | US | claimed |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2024-05-23 | — | — | US | disclosed |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION | 2024-05-02 | — | — | US | disclosed |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4299064-A2 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3641748-B1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | CLEVELAND CLINIC FOUND (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3752201-B1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | UNIV FRIEDRICH ALEXANDER ER (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210186991-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2021-06-24 | — | — | US | disclosed |
| US-20070099235-A1 | Method for designing surfaces | BIO-LAYER PTY LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
| US-20070099235-A1 | Method for designing surfaces | BIO-LAYER PTY LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
| US-20070099235-A1 | Method for designing surfaces | BIO-LAYER PTY LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
| US-6476083-B1 | Alumina dispersant, alumina dispersion liquid, agent for treating inkjet-printing materials, and inkjet-printing materials | TAIHO INDUSTRIES CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-5790627-A | Method and apparatus for observing a specimen using an X-ray microscope | RESEARCH DEVELOPMENT CORP. (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0150706-B1 | COTELOMER COMPOUNDS | CIBA-GEIGY AG (CH) | 1989-05-03 | — | — | EP | disclosed |
| EP-0150706-A2 | Cotelomer compounds | CIBA-GEIGY AG (CH) | 1985-08-07 | — | — | EP | disclosed |
| EP-0061444-B1 | METHOD FOR REMOVING HYDROGEN SULFIDE FROM GAS STREAMS | UNION OIL COMPANY OF CALIFORNIA (US) | 1985-05-22 | — | — | EP | disclosed |
| US-4283379-A | WASHING SOLUTION OF SOLUBILIZED VANADIUM, WATER SOLUBLE NONQUINONE AROMATIC COMPOUNDS, THIOCYANATE IONS, AND A CARBOXYLATE COMPLEXING AGENT | UNION OIL COMPANY OF CALIFORNIA (US) | 1981-08-11 | — | — | US | disclosed |
| US-4084983-A | ALUMINUM FLAKES ON A COATING OF ALUMINUM HYDROXIDE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | SLC5A2, SLC5A1, MAT1A | MPL 1968/4885CTRC 4265/4885MEN1 41/4885 |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | MAOB, DAO, ESD | MPL 1973/4885CTRC 2165/4885MEN1 845/4885 |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | SLC5A2, SLC5A1, MAT1A | MPL 1968/4885CTRC 4265/4885MEN1 41/4885 |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | MPL 2524/4885CTRC 2775/4885MEN1 1478/4885 |
| US-20210186991-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | MPL 1973/4885CTRC 2165/4885MEN1 845/4885 |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | MPL 1973/4885CTRC 2165/4885MEN1 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.